Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Citation: European Cardiology Review 2021;16:e05.
Citation: European Cardiology Review 2021;16:e04.
Citation: US Cardiology Review 2021;15:e01.
Citation: European Cardiology Review 2020;15:e56.